Press Release
09 February 2023 08:00:00 CET

Invitation to presentation of the year-end report 2022

Oncopeptides AB (publ) a biotech company focused on the commercialization, research and development of therapies for difficult-to-treat hematological diseases, will publish the report for the fourth quarter and the 2022 year-end report, at 08:00 (CET) on February 16, 2023.

Investors, financial analysts, and media are invited to participate in a webcast and a following QnA session at 09:00 CET on the same day. The event will be hosted by Monica Shaw, CEO, together with Holger Lembrér, CFO, and the presentation will be held in English.

If you wish to participate via the webcast, please use the link below. Via the webcast you can ask written questions.
https://ir.financialhearings.com/oncopeptides-q4-2022

If you wish to participate via teleconference, please register on the link below. After the registration you will be provided a phone number and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://conference.financialhearings.com/teleconference/?id=5004216

For more information, please contact:
Rolf Gulliksen, Global Head of Corporate Communications, Oncopeptides AB (publ.)
E-mail: rolf.gulliksen@oncopeptides.com
Cell phone: + 46 70 262 96 28

About Oncopeptides
Oncopeptides is a biotech company focused on commercialization, research, and development of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform, PDC, to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US. On December 7, 2022, the FDA recommended that the Company voluntarily withdraw the US marketing authorization for Pepaxto.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com.

Attachments

Invitation to presentation of the year-end report 2022